Literature DB >> 4055942

High-performance liquid chromatographic studies on non-mercapt in equilibrium with mercapt conversion of human serum albumin. II.

M Sogami, S Era, S Nagaoka, K Kuwata, K Kida, J Shigemi, K Miura, E Suzuki, Y Muto, E Tomita.   

Abstract

High-performance liquid chromatographic (HPLC) analysis of human serum albumin (HSA) on a GS-520 column with 0.03 M sodium phosphate buffer-0.15 M sodium sulphate (pH 6.87) showed three peaks, the principal component corresponding to human mercaptalbumin (HMA) and the secondary and tertiary components to nonmercaptalbumin (HNA). Using HPLC analysis, the nonmercapt----mercapt conversion of HSA during haemodialysis and the mercapt----nonmercapt conversion after haemodialysis in chronic renal failure were re-confirmed, indicating that HMA is a covalent carrier protein for sulphur-containing amino acids. Fractions of HMA in various liver diseases were significantly lower than those of healthy male adults.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4055942     DOI： 10.1016/s0021-9673(01)83283-0

Source DB:  PubMed          Journal:  J Chromatogr


  17 in total

1.  Difference in redox status of serum and aqueous humor in senile cataract patients as monitored via the albumin thiol-redox state.

Authors:  Kenji Kawai; Tomoya Hayashi; Yukie Matsuyama; Takeshi Minami; Seiichi Era
Journal:  Jpn J Ophthalmol       Date:  2010-12-30       Impact factor: 2.447

Review 2.  Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties.

Authors:  K Oettl; R E Stauber
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

3.  In vitro and in vivo properties of recombinant human serum albumin from Pichia pastoris purified by a method of short processing time.

Authors:  H Watanabe; K Yamasaki; U Kragh-Hansen; S Tanase; K Harada; A Suenaga; M Otagiri
Journal:  Pharm Res       Date:  2001-12       Impact factor: 4.200

4.  A lower level of reduced albumin induces serious cardiovascular incidence among peritoneal dialysis patients.

Authors:  Hiroyuki Terawaki; Yukie Matsuyama; Nanae Matsuo; Makoto Ogura; Jun Mitome; Akihiko Hamaguchi; Tomoyoshi Terada; Seiichi Era; Tatsuo Hosoya
Journal:  Clin Exp Nephrol       Date:  2012-02-23       Impact factor: 2.801

5.  Assessment of albumin removal from an immunoaffinity spin column: critical implications for proteomic examination of the albuminome and albumin-depleted samples.

Authors:  Rebekah L Gundry; Melanie Y White; Julie Nogee; Irina Tchernyshyov; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2009-04       Impact factor: 3.984

6.  Human astrocytes and aortic endothelial cells actively convert the oxidized form of albumin to the reduced form: reduced albumin might participate in redox regulation of nerve and blood vessel systems.

Authors:  Yukie Matsuyama; Tomoya Hayashi; Hiroyuki Terawaki; Tsuneo Negawa; Tomoyoshi Terada; Yukio Okano; Seiichi Era
Journal:  J Physiol Sci       Date:  2009-03-10       Impact factor: 2.781

7.  Covalent binding of a bucillamine derivative with albumin in sera from healthy subjects and patients with various diseases.

Authors:  R Narazaki; M Otagiri
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

8.  Albumin thiol oxidation and serum protein carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease.

Authors:  Yukie Matsuyama; Hiroyuki Terawaki; Tomoyoshi Terada; Seiichi Era
Journal:  Clin Exp Nephrol       Date:  2009-04-11       Impact factor: 2.801

9.  Commercially Supplied Amine-Modified siRNAs May Require Ultrafiltration prior to Conjugation with Amine-Reactive Compounds.

Authors:  Shannen Lau; Bim Graham; Ben J Boyd; Colin W Pouton; Paul J White
Journal:  J Nucleic Acids       Date:  2011-05-29

10.  Oxidative stress and inflammation in renal patients and healthy subjects.

Authors:  Diana M Lee; Kenneth W Jackson; Nicholas Knowlton; Joshua Wages; Petar Alaupovic; Ola Samuelsson; Aso Saeed; Michael Centola; Per-Ola Attman
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.